AI drug design debate: thalidomide's lesson shows clinical trials still matter
basedjensen · x · 2026-10-11
A debate on AI-designed drugs: one user cites thalidomide — where an enantiomer sign error caused birth defects — to question claims that verification is solved while verifiers are being made jobless.
basedjensen pushes back: we don't even know how half our drugs work, but clinical trials exist for a reason — nobody is injecting millions of people with a drug from a "cocktail machine," AI-designed or otherwise.
Related event: Debate Erupts Over AI-Designed Drugs No One Can Explain(3 posts)→
More from AGI Musings
- Trillions of Tokens Burned, Yet Bad Software Persists as if AI Never Happened — sytelus · 2026-10-12
- Where's the line on speeding up others' code? Anthropic's protein kernels spark debate — jmschreiber91 · 2026-10-12
- Leverage = capability x concurrency x duty cycle: the overlooked bet in AI agents — nbaschez · 2026-10-12
- The Question Before the Question: Building the Conditions for AI 'Self' to Emerge — Artreju · 2026-10-12
- Lean proofs can't settle moral philosophy: the dispute lives in the axioms — AndrewSchmidtFC · 2026-10-12
- Benjamin Bratton unveils Agentworld, Antikythera's research initiative on hybrid human-AI societies — bratton · 2026-10-12